Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Takeda Pharmaceutical Company Limited    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Takeda Pharmaceutical : expects net loss in FY 2019 due to Shire buyout cost

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/14/2019 | 08:04am EDT

Takeda Pharmaceutical Co. said Tuesday its profit declined in the business year ended March and it expects to book a net loss of 383 billion yen ($3.5 billion) in the current year due to costs related to its buyout earlier this year of Irish drugmaker Shire Plc.

But Japan's largest drugmaker said its core operations continued to fare well, with such key products as ulcerative colitis and multiple myeloma treatments posting higher sales.

In the just ended business year, Takeda's group net profit fell 41.6 percent to 109.13 billion yen. Without the effects of the takeover of Shire, the company said it saw a 67.4 percent rise in net profit.

Takeda and other major Japanese pharmaceutical companies have sought to improve their competitiveness in the global market through acquisitions of foreign firms. Takeda has aggressively bought European and U.S. drugmakers to expand its product lineup and development pipeline.

With the acquisition of Shire, Takeda projects its sales in the year to March 2020 will climb 57.4 percent to 3.30 trillion yen. If achieved it would be the first Japanese pharmaceutical company to record sales of over 3 trillion yen.

The net loss forecast for the current business year will mainly result from a write-down of Shire's inventories. Without the Shire-related costs, Takeda's sales and profit would likely be higher from the previous year, it said.

The 6.2 trillion yen takeover of Shire was completed in January, making it the biggest-ever Japanese acquisition of a foreign firm.

==Kyodo

© Kyodo News International, Inc., source Newswire

Stocks mentioned in the article
ChangeLast1st jan.
SHIRE 2.42% 4690 End-of-day quote.0.00%
TAKEDA PHARMACEUTICAL COMPANY LIMITED -1.28% 3780 End-of-day quote.4.42%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TAKEDA PHARMACEUTICAL COMP
06:38aTAKEDA PHARMACEUTICAL : Retrospective Real-World Comparative Analysis Highlights..
AQ
02:01aTAKEDA PHARMACEUTICAL : Retrospective Real-World Comparative Analysis Highlights..
PU
01:02aTAKEDA PHARMACEUTICAL : Retrospective Real-World Comparative Analysis Highlights..
BU
10/15Takeda sells Mideast, Africa drug portfolio to Switzerland's Acino
RE
10/15TAKEDA PHARMACEUTICAL : Agrees to divest select otc and non-core assets to acino..
PU
10/01TAKEDA PHARMACEUTICAL : Working Mother Names Takeda as One of the 2019 100 Best ..
AQ
09/27TAKEDA PHARMACEUTICAL : New Data Presented at World Sleep Congress Demonstrate E..
AQ
09/27TAKEDA PHARMACEUTICAL : New Data Presented at World Sleep Congress Demonstrate E..
AQ
09/27TAKEDA PHARMACEUTICAL CO LTD : Ex-dividend day for interim dividend
FA
09/25TAKEDA PHARMACEUTICAL : New Data Presented at World Sleep Congress Demonstrate E..
BU
More news
Financials (JPY)
Sales 2020 3 327 B
EBIT 2020 -47 541 M
Net income 2020 -292 922 M
Debt 2020 4 304 B
Yield 2020 4,76%
P/E ratio 2020 -20,1x
P/E ratio 2021 38,2x
EV / Sales2020 3,07x
EV / Sales2021 2,93x
Capitalization 5 918 B
Technical analysis trends TAKEDA PHARMACEUTICAL COMP
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 5 305,38  JPY
Last Close Price 3 780,00  JPY
Spread / Highest target 66,7%
Spread / Average Target 40,4%
Spread / Lowest Target -2,12%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
Costa Saroukos Chief Financial Officer
Andrew S. Plump Director, Chief Medical & Scientific Officer
Yasuhiko Yamanaka Director
Masato Iwasaki Director & President-Japan Pharma Business Unit
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED4.42%54 291
JOHNSON & JOHNSON-1.05%337 021
ROCHE HOLDING AG18.88%250 869
MERCK AND COMPANY10.82%216 813
PFIZER-16.47%201 662
NOVARTIS15.10%198 751